Should I Buy ALGS? ALGS 2026 Analysis

Should You Buy Aligos Therapeutics Inc (ALGS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.060

1 Day change

-6.17%

52 Week Range

29.540

Analysis Updated At

2026/01/28

ALGS is not a good buy right now for a Beginner long-term investor with $50k–$100k who wants to act immediately. The setup is technically neutral-to-weak, options data is thin/unreliable, and fundamentals still show steep revenue contraction and sizable losses. While UBS initiated with a Buy and a $20 target and hedge funds have been increasing buying, the absence of near-term catalysts/news and very high volatility make the risk/reward unattractive for a beginner long-term entry today.

Technical Analysis

Price context: pre-market ~8.75, sitting slightly above the pivot (8.485), with nearby resistance at 9.18 and support at 7.789. Trend/indicators: MACD histogram is negative (-0.0315) but contracting (selling pressure easing, not reversed). RSI(6) ~51.5 is neutral (no momentum edge). Moving averages are converging, consistent with consolidation rather than a clear uptrend. Tactical read: This looks like a range/indecision zone; upside is capped near 9.18–9.61 unless momentum improves, while a break below 8.49 increases downside risk toward ~7.79. Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options snapshot (dated 2025-11-19): Open interest and volume fields are largely missing, while put-call ratios show 0.0, which typically implies call-dominance or incomplete data. Historical volatility is extremely high (~122%), signaling a highly speculative profile. Overall, options sentiment cannot be confidently inferred beyond “very high risk/volatility.”

Technical Summary

Sell

Buy

Positive Catalysts

Hedge fund activity: Buying increased ~162.3% last quarter (supportive of sentiment).
Analyst action: UBS initiated coverage with a Buy rating and a $20 price target (bullish framing).
Pattern-based forecast included in dataset suggests modest positive drift over 1 week to 1 month (approx. +1.52% / +3.9%), though not a strong edge.

Neutral/Negative Catalysts

No news/catalysts in the past week (no clear event-driven driver).
Technical picture is not in a confirmed uptrend (neutral RSI, MACD still below zero, moving averages converged).
Very high volatility (HV ~122%) increases the chance of sharp drawdowns—especially problematic for beginners.
No insider buying trend (insiders neutral). No supportive politician/congress activity reported.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue: 741K, down -41.61% YoY (weak top-line trend). Net income: -31.537M, improved +63.75% YoY (loss narrowed, but still deeply negative). EPS: -3.04, worse YoY (down -0.98% YoY per dataset). Overall: Financials show continued cash-burn/loss profile with declining revenue, which is a weak foundation for a beginner-focused long-term buy today.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: On 2026-01-07, UBS initiated coverage with a Buy rating and a $20 price target. Wall Street pro view (pros): Potential biotech inflection into 2026; initiation suggests perceived upside from current levels. Wall Street pro view (cons): Coverage is limited (single initiation provided), and without near-term catalysts/news, the stock can remain sentiment-driven and volatile rather than fundamentally re-rating quickly.

3 Analyst Rating

Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 81.67 USD with a low forecast of 20 USD and a high forecast of 175 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.590

Low

Averages

81.67

High

175

Current: 8.590

Low

Averages

81.67

High

175

UBS

Michael Yee

Buy

initiated

$20

AI Analysis

2026-01-07

Reason

UBS

Michael Yee

Price Target

$20

AI Analysis

2026-01-07

initiated

Buy

Reason

UBS analyst Michael Yee initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $20 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

H.C. Wainwright

initiated

$50

2025-08-18

Reason

H.C. Wainwright

Price Target

$50

2025-08-18

initiated

Reason

H.C. Wainwright assumed coverage of Aligos Therapeutics with a Buy rating and $50 price target. The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALGS

Unlock Now

ALGS Should I Buy

ALGS Should I Buy

Should You Buy Aligos Therapeutics Inc (ALGS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch